ImmunityBio, Inc. Common Stock (IBRX) — Analysis Summary
ImmunityBio, Inc. Common Stock (IBRX) has a market cap of $7.88B with year-over-year revenue growth of +668.3%. Net margin stands at -310.2%. The stock trades at a P/E ratio of -9.2.
Key Takeaways
- Revenue changed +668.3% year-over-year
- Net margin of -310.2%
- P/E ratio of -9.2
Compared to other companies in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector, IBRX posted revenue growth of +668.3% and trades at a P/E of -9.2.
Disclaimer: This is not financial advice. Data sourced from SEC EDGAR and Polygon.io. Past performance does not guarantee future results. Always conduct your own research before making investment decisions.